A Possible Cluster of AEFI (Adverse Event Following Vaccination) Following AZD1222 (Covishield) Vaccination in India?

 Abstract

In order to mitigate the spread of the COVID-19 infection in India, the Indian government granted approval for the emergency use of Oxford-AstraZeneca’s COVID-19 (coronavirus disease 2019) vaccine AZD1222 (Covishield). The biggest large-scale COVID-19 vaccination drive in the world is being carried out continuously till date in India. In this research article, a possible cluster of AEFI (Adverse Event Following Vaccination) following AZD1222 (Covishield) vaccination in India has been briefly presented.

Read more about this article: https://juniperpublishers.com/ijoprs/IJOPRS.MS.ID.555676.php

Read more Juniper Publishers Google Scholar Articles: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=Y8LS2LwAAAAJ&citation_for_view=Y8LS2LwAAAAJ:70eg2SAEIzsC

 

Comments

Popular posts from this blog

SARS CoV-2 Vaccination Autoimmunity, Antibody Dependent Covid-19 Enhancement and Other Potential Risks: Beneath the Tip of the Iceberg

Effects of Selenium Nanoparticles on Bleomycin-Induced Pulmonary Fibrosis in Rats

Complication and Sequelae of Pulmonary Tuberculosis: A Tertiary Care Center Experience